EICHOR
● Recruiting
Iadademstat + SBRT With Atezo in ES-SCLC
Condition: Extensive Stage Small Cell Lung Cancer (ES-SCLC) · Sponsor: Yale University
About this study
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the completion of initial platinum-based treatment are eligible for enrollment.
This description comes directly from the study's public registry record.
Talk to the study team
Carole Ramm · 203-737-5801 · carole.ramm@yale.edu
Always discuss trial participation with your own doctor first.
Locations (1)
| Yale University | New Haven, Connecticut, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07113691